Moreover, considering the pivotal role of the NF-κB pathway in the pathogenesis of metabolic cardiomyopathy has been adequately validated [36, 37], it may be the most critical target that mediates dapagliflozin's anti-inflammatory effects in diabetes. The gene discussed is NFKB1; the disease is diabetes mellitus.